<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977210</url>
  </required_header>
  <id_info>
    <org_study_id>PH1/098</org_study_id>
    <nct_id>NCT00977210</nct_id>
  </id_info>
  <brief_title>Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Trial of OXi4503 (a Vascular Disrupting Agent) Given by 3 Weekly Intravenous Infusions to Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mateon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mateon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the Maximum Tolerated Dose (MTD) of OXi4503 given
      by weekly infusions to patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly intravenous infusions.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of OXi4503.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>OXi4503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXi4503</intervention_name>
    <description>OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.</description>
    <arm_group_label>OXi4503</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven cancer.

          -  Written informed consent.

          -  Age &gt;/= 18 years.

          -  Life expectancy of at least 12 weeks.

          -  World Health Organization (WHO) performance status of 0 or 1.

          -  Adequate Hematological and biochemical indices to support investigational therapy.

          -  All women of childbearing potential (WOCBP) must have a negative serum pregnancy test.

          -  WOCBP and fertile men and their partners must agree to use an effective form of
             contraception during the study and for 90 days after the last dose of study
             medication.

          -  Measurable and evaluable disease.

          -  All toxic manifestations of previous treatment must have resolved.

          -  Able to undergo MRI scanning.

        Exclusion Criteria:

          -  Radiotherapy, endocrine therapy, immunotherapy or chemotherapy during the previous
             four weeks (six weeks for nitrosureas and Mitomycin-C) prior to treatment.

          -  Pregnant and lactating women.

          -  Major thoracic and/or abdominal surgery in the preceding four weeks from which the
             patient has not yet recovered.

          -  Patients which have active uncontrolled infections.

          -  Patients with any other condition that in the Investigator's opinion would not make
             the patient a good candidate for the clinical trial.

          -  Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human
             Immunodeficiency Virus (HIV).

          -  Previous or ongoing cardiac conditions.

          -  Uncontrolled hypertension.

          -  Patients taking any drug known to prolong the QTc interval.

          -  Patients who have had any ischaemic or vascular damage from previous radiotherapy.

          -  Patients taking warfarin or heparin.

          -  Patients taking naproxen.

          -  Patients taking supplements or multivitamins containing vitamin C.

          -  Patients should not be taking any other investigational drug for the duration of the
             study.

          -  Patients with brain metastases or neurological tissue involvement of the spinal
             column.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRUK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRUK Investigational Site</name>
      <address>
        <city>Middlesex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>October 28, 2011</last_update_submitted>
  <last_update_submitted_qc>October 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>oxi4503</keyword>
  <keyword>oxigene</keyword>
  <keyword>cruk</keyword>
  <keyword>solid tumors</keyword>
  <keyword>VDA</keyword>
  <keyword>vascular disrupting agent</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

